Andrew Armstrong

Andrew Armstrong at Duke Cancer Institute leads clinical development of novel androgen receptor-targeting approaches in mCRPC, including PROTAC AR degraders such as ARV-110. His research addresses mechanisms of enzalutamide and abiraterone resistance and how novel AR-targeting approaches can overcome them. He contributes to cooperative group trials and has published extensively on prognostic and predictive biomarkers in metastatic prostate cancer. His lab-to-clinic translational approach has advanced next-generation hormonal therapies.